leadf
logo-loader
viewAlgernon Pharmaceuticals Inc.

Algernon enrolls 50% of patients in multinational Phase 2b/3 human study of Ifenprodil to treat coronavirus

The current study with a target of 150 patients will be completed by November 2020, with a planned data readout before the end of the fourth quarter

Algernon Pharmaceuticals Inc. - Algernon enrolls 50% of patients in multinational Phase 2b/3 human COVID-19 study of Ifenprodil
Algernon believes that Ifenprodil could reduce the infiltration of neutrophils and T-cells into the lungs, where they can release cytokines, that can result in the highly problematic cytokine storm

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) said on Tuesday that it has enrolled 75 patients for its multinational Phase 2b/3 human trial of its lead drug NP-120 (Ifenprodil) as a potential treatment for coronavirus (COVID-19) sufferers, which is 50% of its enrollment target.

The Vancouver-based clinical-stage pharma company has been nimble — and unusual — in its hunt for a COVID-19 drug. It has taken a generic neurological drug that Sanofi developed in the 1970’s called Ifenprodil, which is approved for use in South Korea and Japan, and is attempting to repurpose it as a potential COVID-19 treatment.

The company’s current study with a target of 150 patients will be completed by November 2020, with a planned data readout before the end of the fourth quarter this year.

READ: Algernon Pharmaceuticals gets Speculative Buy debut rating from Mackie Capital Research

Algernon said the trial has begun as a Phase 2b study of patients and, with positive preliminary data, the clinical trial will move directly into a Phase 3 trial. The data from the Phase 2b study will determine the number of patients needed to reach statistical significance in the Phase 3 trial.

Patients are currently randomized in a one-to-one manner and will either be treated using an existing standard of care, or standard of care plus Ifenprodil 60 milligrams (taken as one 20 mg tablet three-times daily), or standard of care plus Ifenprodil 120 mg (taken as two 20 mg tablets three-times daily) for two weeks.

Over the testing period, doctors will observe whether there is an improvement in a number of secondary endpoints, including mortality, blood oxygen levels, and time spent in intensive care.

Algernon believes that Ifenprodil could reduce the infiltration of neutrophils and T-cells into the lungs, where they can release glutamate and cytokines. The latter can result in the highly problematic cytokine storm that contributes to the loss of lung function, and ultimately death, in COVID-19 patients.

Algernon is also steadily advancing its lead drug Ifenprodil as a possible treatment for idiopathic pulmonary fibrosis, acute lung injury, and chronic cough.

Contact the author Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.295 CAD

CSE:AGN
Market: CSE
Market Cap: $32.47 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...

FOR OUR FULL DISCLAIMER CLICK HERE

Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll...

Algernon Pharmaceutical (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has now enrolled a third of their patients in the Phase 2B/3 study of their repurposed drug Ifenprodil. Moreau discusses hitting that mark and also...

on 09/02/2020

2 min read